Pfizer's Lyrica doesn't meet endpoint in epilepsy study
Pfizer Inc. said late Friday one of its drugs did not meet set goals for the treatment of epilepsy in a late stage clinical trial. Pfizer said a Phase 3 clinical trial showed its drug Lyrica did not significantly reduce seizures in epilepsy patients compared with those given a placebo. Lyrica is already approved by the Food and Drug Administration to treat fibromyalgia, diabetic nerve pain, spinal cord injury nerve pain and pain after shingles. Pfizer shares, which closed up less than 0.1% at $41.95, were flat after hours.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.